Form 4: Ionis Pharmaceuticals Director Joseph Klein III Receives Stock Options and Restricted Stock Units

Director Joseph Klein III received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Summary

• On July 1, 2024, Joseph Klein III, a director of Ionis Pharmaceuticals, received stock options and restricted stock units (RSUs) as part of the company's non-employee director compensation policy.
• The stock options grant was for 10,111 shares with an exercise price of $47.11, vesting on the earlier of July 1, 2025, or the next annual meeting, and expiring on June 30, 2034.
• The RSU grant was for 4,079 units, each representing one share of Ionis common stock or its equivalent cash value, vesting on the earlier of July 1, 2025, or the next annual meeting.
• Klein has elected to defer delivery of the shares underlying the RSUs until separation from service or a change in control of the company.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.
• The deferred delivery of RSU shares may provide tax benefits to the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Equity compensation is a common practice for directors of publicly traded companies to align their interests with shareholders and incentivize performance.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice among publicly traded biotechnology companies like Ionis Pharmaceuticals.
• The specific amounts and vesting schedules can vary based on company size, performance, and industry benchmarks.
• Comparable companies such as Alnylam Pharmaceuticals and Biogen also utilize equity-based compensation for their board members.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates